1(5-Methyl-thien-2-yl) 3,4-dihydro-4,4-dimethyl-7-naphthaldehyde | 204449-12-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1(5-Methyl-thien-2-yl) 3,4-dihydro-4,4-dimethyl-7-naphthaldehyde
• 英文别名: 5,5-dimethyl-8-(5-methylthiophen-2-yl)-6H-naphthalene-2-carbaldehyde
• CAS: 204449-12-7
• 化学式: C₁₈H₁₈OS
• 分子量: 282.406
• InChiKey: DLYXATCPFUFKKH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1(5-Methyl-thien-2-yl) 3,4-dihydro-4,4-dimethyl-7-naphthaldehyde 、 ethyl 4-(diethoxyphosphoryl-3,3-dimethoxypropyl)benzoate 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 Ethyl 4-[1-(2,2-dimethoxyethyl)-2-{1-(5-methyl-thien-2-yl)3,4-dihydro-4,4-dimethyl-naphthalen-7-yl}-(E)-ethen-1-yl]-benzoate
  参考文献：
  名称：

  Benzo\x9b1,2-g!-chrom-3-ene and benzo\x9b1,2-g!-thiochrom-3-ene derivatives

  摘要：

  式为##STR1##的化合物，在规范中定义的符号具有类似于视黄醇、视黄醇拮抗剂和/或视黄醇逆激动剂的生物活性。

  公开号：

  US05728846A1
• 作为产物：
  描述：

  2-lithio-5-methylthiophene 在 叔丁基锂 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1(5-Methyl-thien-2-yl) 3,4-dihydro-4,4-dimethyl-7-naphthaldehyde
  参考文献：
  名称：

  A new class of potent rar antagonists: Dihydroanthracenyl, benzochromenyl and benzothiochromenyl retinoids

  摘要：

  The synthesis and biological activity of a novel series of tricyclic retinoic acid receptor antagonists are described. These compounds bind with high affinity to the RARs and are potent antagonists of retinoid function in in vitro and in vivo systems. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00077-3

文献信息

• Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
  申请人：——

  公开号：US20030130515A1

  公开（公告）日：2003-07-10

  Compounds of the formula 1 where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist and/or retinoid inverse-agonist-like biological activity.

  具有以下式子1的化合物，在规范中定义的符号具有相应的含义，具有类视黄醇、类视黄醇拮抗剂和/或类视黄醇反向激动剂样生物活性。
• Benzo[1,2-G]-chrom-3-ene, and benzo[1,2-G]-thiochrom-3-ene derivatives
  申请人：Allergan Sales, Inc.

  公开号：US06087505A1

  公开（公告）日：2000-07-11

  Compounds of the formula ##STR1## where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist and/or retinoid inverse-agonist-like biological activity.

  式子为##STR1##的化合物，其中符号的含义在说明书中已定义，具有视黄醇、视黄醇拮抗剂和/或视黄醇逆激动剂类似的生物活性。
• Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
  申请人：Allergan, Inc.

  公开号：US07166726B2

  公开（公告）日：2007-01-23

  Disclosed herein are compounds of the formula wherein R1 is independently H or alkyl of 1 to 6 carbons; R2 is optional and is defined as lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; n is an integer of between 0 and 2; o is an integer between 0 and 3; R3 is hydrogen, lower alkyl of 1 to 6 carbons, F, Cl, Br or I; R4 is heteroaryl or (R5)p-heteroaryl where the heteroaryl group is 5-membered or 6-membered and has 1 to 3 heteroatoms selected from the group consisting of O, S, and N; p is an integer having the values of 0–5; R5 is F, Cl, Br, I, NO2, N(R8)2, N(R8)CORO8, N(R8)CON(R8)2, OH, OCOR8, OR8, CN, COOH, COOR8, C1-10 alkyl, fluoro substituted C1-10 alkyl, C2-10 alkenyl having 1 to 3 double bonds, C2-10 alkynyl having 1 to 3 triple bonds, or a (trialkyl)silyl or (trialkyl)silyloxy group where the alkyl groups independently have 1 to 6 carbons; A is (CH2)q where q is 0–5, C3-6 branched alkyl, C3-6 cycloalkyl, C2-6 alkenyl having 1 or 2 double bonds, or C2-6 alkynyl having 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COORO8, CONR9R10, CH2OH, CH2OR11, CH2OCOR11, CHO, CH(OR12)2, CHOR13O, COR7, CR7(OR12)2, CR7OR13O, or Si(C1-6alkyl)3; R7 is C1-5 alkyl, C3-5 cycloalkyl, or C2-5 alkenyl; R8 is C1-10 alkyl, C1-10 (trimethylsilyl)alkyl, or C5-10 cycloalkyl; R9 and R10 are independently hydrogen, C1-10 alkyl, C5-10 cycloalkyl, phenyl or R12-phenyl; R11 is C1-6 alkyl, phenyl, or R12-phenyl; R12 is C1-6 alkyl; and R13 is divalent alkyl radical of 2–5 carbons.

  本文揭示的是以下化合物：其中R1独立地为H或1至6个碳的烷基；R2是可选的，并定义为1至6个碳的低烷基，F，Cl，Br，I，CF3，1至6个碳的氟代烷基，OH，SH，1至6个碳的烷氧基或烷硫基；n为0至2的整数；o为0至3的整数；R3为氢，1至6个碳的低烷基，F，Cl，Br或I；R4为杂环芳基或（R5）p-杂环芳基，其中杂环芳基为5元或6元，并具有从O，S和N组成的1至3个杂原子；p为0至5的整数；R5为F，Cl，Br，I，NO2，N（R8）2，N（R8）CORO8，N（R8）CON（R8）2，OH，OCOR8，OR8，CN，COOH，COOR8，C1-10烷基，氟代C1-10烷基，具有1至3个双键的C2-10烯基，具有1至3个三键的C2-10炔基，或（三烷基）硅基或（三烷基）硅氧基，其中烷基独立地具有1至6个碳；A为（CH2）q，其中q为0至5，C3-6支链烷基，C3-6环烷基，具有1或2个双键的C2-6烯基，或具有1或2个三键的C2-6炔基；B为氢，COOH或其药学上可接受的盐，COORO8，CONR9R10，CH2OH，CH2OR11，CH2OCOR11，CHO，CH（OR12）2，CHOR13O，COR7，CR7（OR12）2，CR7OR13O或Si（C1-6烷基）3；R7为C1-5烷基，C3-5环烷基或C2-5烯基；R8为C1-10烷基，C1-10（三甲基硅基）烷基或C5-10环烷基；R9和R10独立地为氢，C1-10烷基，C5-10环烷基，苯基或R12-苯基；R11为C1-6烷基，苯基或R12-苯基；R12为C1-6烷基；R13为2-5个碳的双价烷基基团。
• ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO [1,2-G]CHROM-3-ENE, BENZO[1,2-G]-THIOCHROM-3-ENE AND BENZO [1,2-G]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY
  申请人：Allergan

  公开号：US06538149B1

  公开（公告）日：2003-03-25

  Compounds of the formula where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist and/or retinoid inverse-agonist-like biological activity.

  符号在规范中定义的公式化合物具有类视黄醇、类视黄醇拮抗剂和/或类视黄醇反向激动剂样的生物活性。
• ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]-THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY
  申请人：Allergan Sales, Inc.

  公开号：EP0948478B1

  公开（公告）日：2002-04-10